Shares of GSK plc (NYSE: GSK) experienced a significant surge of over 5% in pre-market trading after the company confirmed a confidential settlement with James Goetz. As a result, the case filed in California state court, scheduled for trial on July 24, 2023, will be dismissed.

The settlement allows GSK to avoid prolonged litigation and potential distractions. It's important to note that GSK does not admit any liability in this settlement and remains committed to vigorously defending itself in all other Zantac cases based on factual evidence and scientific grounds.

In pre-market trading, $GSK is currently trading at $36.79, reflecting a gain of $2.11 or 6.08%.

In other news, Apogee Enterprises, Inc. (Nasdaq: APOG) reported first-quarter fiscal 2024 adjusted EPS of $1.05, surpassing the consensus estimate of $0.90.

The company is raising its outlook for full-year diluted EPS for fiscal 2024 to a range of $4.15 to $4.45, up from the previously announced range of $3.90 to $4.25. The consensus estimate for the period is $4.05.

$APOG is trading at $44.40 in pre-market, up $0.63 or 1.44%.

Furthermore, Smith & Wesson Brands, Inc. (Nasdaq: SWBI) announced fourth-quarter fiscal 2023 adjusted EPS of $0.32, exceeding the consensus estimate of $0.27.

The Board of Directors has authorized a 20% increase in the company's quarterly dividend, now set at $0.12 per share.

$SWBI is trading at $12.16 in pre-market, showing an increase of $0.92 or 8.19%.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)